Ye Feng, Zhong Xiaorong, Qiu Yan, Yang Libo, Wei Bing, Zhang Zhang, Bu Hong
Laboratory of Pathology, State Key Laboratory of Biotherapy, National Collaborative Innovation Center for Biotherapy, Chengdu, China.
Cancer Center, State Key Laboratory of Biotherapy, National Collaborative Innovation Center for Biotherapy, Chengdu, China.
J Breast Cancer. 2017 Jun;20(2):142-149. doi: 10.4048/jbc.2017.20.2.142. Epub 2017 Jun 26.
Metastasis and local recurrence are the primary causes of treatment failure and patient death in breast cancer. The aim of this study was to validate a metastasis- and local recurrenceassociated biomarker for prognostic evaluation and planning treatment strategies.
Formalin-fixed, paraffin-embedded tissues from a cohort of 312 patients (all stage II and III) were used. The prevalence of CD49f cells in the patients' tumors was analyzed and correlated with clinical characteristics to determine its prognostic and clinical implications.
CD49f tumor cells were found in a minority of tumors, with 62.8% of the samples showing not a single cell of this subtype. In the clinical characteristics analysis, which were performed with t-tests, CD49f tumors were not associated with age, tumor size, World Health Organization grade, nodal status, human epidermal growth factor receptor 2 status, progesterone receptor status, or estrogen receptor status, although they were significantly associated with disease recurrence (distant metastasis or/and local recurrence). Univariate survival analysis using the Kaplan-Meier method showed that CD49f tumors were associated with markedly decreased disease-free survival (DFS); the same result was found using multivariate Cox analysis, even when only chemotherapy-treated patients were analyzed.
Our results indicated that breast tumors with CD49f cancer cells are associated with an increased risk for disease recurrence after initial surgery with poor clinical outcomes (decreased DFS). Therefore, as it requires testing for only one additional protein, adding CD49f testing to conventional surgical pathology is a strategy that has great potential for prognostic and treatment-guidance purposes.
转移和局部复发是乳腺癌治疗失败和患者死亡的主要原因。本研究的目的是验证一种与转移和局部复发相关的生物标志物，用于预后评估和制定治疗策略。
使用来自312例患者（均为II期和III期）队列的福尔马林固定、石蜡包埋组织。分析患者肿瘤中CD49f细胞的发生率，并将其与临床特征相关联，以确定其预后和临床意义。
在少数肿瘤中发现了CD49f肿瘤细胞，62.8%的样本中未发现该亚型的单个细胞。在采用t检验进行的临床特征分析中，CD49f肿瘤与年龄、肿瘤大小、世界卫生组织分级、淋巴结状态、人表皮生长因子受体2状态、孕激素受体状态或雌激素受体状态无关，尽管它们与疾病复发（远处转移或/和局部复发）显著相关。使用Kaplan-Meier方法进行的单因素生存分析表明，CD49f肿瘤与无病生存期（DFS）显著降低相关；即使仅分析接受化疗的患者，多因素Cox分析也得出了相同的结果。
我们的结果表明，含有CD49f癌细胞的乳腺肿瘤与初始手术后疾病复发风险增加及临床结局较差（DFS降低）相关。因此，由于只需检测一种额外的蛋白质，在传统手术病理学中增加CD49f检测是一种具有巨大预后和治疗指导潜力的策略。
